Showing 2081-2090 of 3223 results for "".
- Alcon to Highlight Scientific Program Showcasing Latest Innovations at Virtual ASCRShttps://modernod.com/news/alcon-to-highlight-scientific-program-showcasing-latest-innovations-at-virtual-ascrs/2477746/Alcon will present data that supports advancements in cataract surgery during the virtual American Society of Cataract and Refractive Surgery (ASCRS) 2020 annual meeting, taking place May 16-17. The company will also host a virtual exhibit booth that will provide information on its latest product
- AbbVie Completes Acquisition of Allerganhttps://modernod.com/news/abbvie-completes-acquisition-of-allergan/2477739/AbbVie announced that it has completed its acquisition of Allergan after receiving regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. “We are pleased to reach this important milestone for the company, its em
- The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Millionhttps://modernod.com/news/the-allergan-foundation-doubles-its-covid-19-response-donations-to-4-0-million/2477733/Allergan announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation’s total COVID-19 donations to date, r
- AbbVie, Allergan Gain US Antitrust Clearance for Dealhttps://modernod.com/news/abbvie-allergan-gain-us-antitrust-clearance-for-deal/2477714/The US Federal Trade Commission (FTC) accepted the proposed consent order in connection with AbbVie’s pending $63-billion acquisition of Allergan, the companies announced. The FTC’s decision means that all required antitrust clearances needed for the merger have now been obtained.
- Alnylam, Vir to Advance Experimental RNAi Therapeutic VIR-2703 as Potential COVID-19 Treatmenthttps://modernod.com/news/alnylam-vir-to-advance-experimental-rnai-therapeutic-vir-2703-as-potential-covid-19-treatment/2477702/Alnylam Pharmaceuticals and Vir Biotechnology announced that they plan to develop VIR-2703, an investigational RNAi therapeutic targeting the SARS-CoV-2 genome as an inhalational formulation for the potential treatment or prevention of COVID-19. “To our knowledge, this is one of the
- Certain Hospital Systems Eye a Restart of Elective Procedures Canceled Due to COVID-19https://modernod.com/news/certain-hospital-systems-eye-a-restart-of-elective-procedures-canceled-due-to-covid-19/2477687/Hospital systems are taking the first steps toward reviving elective procedures that have been canceled due to the COVID-19 pandemic, but major concerns about safety and patient confidence remain, according to a FierceHealthcare
- ELT Sight’s ExTra Excimer Laser Trabeculostomy Procedure Receives New CPT Codeshttps://modernod.com/news/elt-sights-extra-excimer-laser-trabeculostomy-procedure-receives-new-cpt-codes/2477680/ELT Sight announced that the American Medical Association (AMA) approved two new Category III Current Procedural Terminology (CPT) codes to report ELT Sight’s ExTra Excimer Laser Trabeculostomy (ELT) procedure. The two new codes, to be used for reporting trabeculostomy ab interno by laser with or
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- Ambulatory Surgery Centers Eligible For New Relief Grant Fundshttps://modernod.com/news/ambulatory-surgery-centers-eligible-for-new-relief-grant-funds-on-april-24/2477642/The Department of Health and Human Services (HHS) announced that, commencing April 24, health care providers, including ASCs, will be eligible to receive grants from a newly available pool of COVID-19 relief funds, according to The Outpatient Ophthalmic Surgery Society (OOSS). These grants are a
- Alexion to Investigate Effects of C5 Inhibition With Ultomiris in Hospitalized Patients With Severe COVID-19https://modernod.com/news/alexion-to-investigate-effects-of-c5-inhibition-with-ultomiris-in-hospitalized-patients-with-severe-covid-19/2477621/Alexion Pharmaceuticals said it plans to initiate a phase 3 study of Ultomiris (ravulizumab-cwvz) in adults with COVID-19 who are hospitalized with severe pneumonia or acute respiratory distress syndrome. The C5 complement inhibitor is currently approved in the US, Europe and Japan for adults wit